SMTI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

27.78M

+5.59%

0.325

-280.56%

28.10M

+19.91%

0.260

-163.41%

29.55M

+14.4%

0.290

-226.09%

Estimates Revision

The market is revising Downward the revenue expectations for Sanara MedTech Inc. (SMTI) for FY2025, with the revenue forecasts being adjusted by -0.76% over the past three months. During the same period, the stock price has changed by -29.59%.

Revenue Estimates for FY2025

Revise Downward

-0.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-53.25%

In Past 3 Month

Stock Price

Go Down

-29.59%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 24.700

Low

36.00

Averages

41.00

High

46.00

Current: 24.700

Low

36.00

Averages

41.00

High

46.00

H.C. Wainwright

Buy

downgrade

$54 -> $36

2025-11-14

Reason

H.C. Wainwright

Price Target

$54 -> $36

2025-11-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Sanara MedTech to $36 from $54 and keeps a Buy rating on the shares following the Q3 report. The company plans to execute its commercial plan and improve operational efficiency to support sustainable revenue growth and improved profitability going forward, the analyst tells investors in a research note.

H.C. Wainwright

Yi Chen

Buy

maintain

$53 -> $54

2025-08-18

Reason

H.C. Wainwright

Yi Chen

Price Target

$53 -> $54

2025-08-18

maintain

Buy

Reason

H.C. Wainwright analyst Yi Chen raised the firm's price target on Sanara MedTech to $54 from $53 and keeps a Buy rating on the shares. The company reported a Q2 beat, the analyst tells investors in a research note.

H.C. Wainwright

Yi Chen

Buy

maintain

$51 -> $53

2025-05-15

Reason

H.C. Wainwright

Yi Chen

Price Target

$51 -> $53

2025-05-15

maintain

Buy

Reason

H.C. Wainwright analyst Yi Chen raised the firm's price target on Sanara MedTech to $53 from $51 and keeps a Buy rating on the shares following the Q1 report. The firm believes Sanara Surgical segment could continue to drive sales growth as the company increases regional sales managers and territories and grows distribution partners.

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$46

2025-03-26

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$46

2025-03-26

Reiterates

Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$50 → $51

2025-03-26

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$50 → $51

2025-03-26

Maintains

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$44

2025-01-23

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$44

2025-01-23

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Sanara Medtech Inc (SMTI.O) is 21.33, compared to its 5-year average forward P/E of -10.35. For a more detailed relative valuation and DCF analysis to assess Sanara Medtech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.35

Current PE

21.33

Overvalued PE

64.88

Undervalued PE

-85.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.19

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

17.31

Undervalued EV/EBITDA

-10.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.63

Current PS

0.00

Overvalued PS

7.10

Undervalued PS

2.15

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SMTI News & Events

Events Timeline

No data

News

7.0

11-24Globenewswire

Investor Notice: Holzer & Holzer, LLC Launches Investigation into Sanara MedTech Inc. (SMTI)

1.0

11-19Newsfilter

Sanara MedTech to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler on December 3rd

4.5

11-15Yahoo Finance

Sanara MedTech (SMTI) Shifts Focus Following THP Division Closure and Quarterly Losses

People Also Watch

Frequently Asked Questions

What is Sanara Medtech Inc (SMTI) stock price today?

The current price of SMTI is 24.7 USD — it has decreased -4.67 % in the last trading day.

What is Sanara Medtech Inc (SMTI)'s business?

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.

What is the price predicton of SMTI Stock?

What is Sanara Medtech Inc (SMTI)'s revenue for the last quarter?

Sanara Medtech Inc revenue for the last quarter amounts to 26.33M USD, increased 21.51 % YoY.

What is Sanara Medtech Inc (SMTI)'s earnings per share (EPS) for the last quarter?

Sanara Medtech Inc. EPS for the last quarter amounts to -3.52 USD, increased 935.29 % YoY.

What changes have occurred in the market's expectations for Sanara Medtech Inc (SMTI)'s fundamentals?

How many employees does Sanara Medtech Inc (SMTI). have?

Sanara Medtech Inc (SMTI) has 141 emplpoyees as of December 16 2025.

What is Sanara Medtech Inc (SMTI) market cap?

Today SMTI has the market capitalization of 220.71M USD.